Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...
A scientific statement has been published by the American College of Cardiology regarding inflammation and cardiovascular disease.
There’s a need in secondary prevention for personalized risk estimates to motivate patients and guide care, researchers say.
Combining an antiplatelet with oral anticoagulants in stroke patients with AF and cardiovascular disease slightly lowers ...
Despite advancements in treatment and prevention, patients with established atherosclerotic cardiovascular disease (ASCVD) ...
An expert discusses the growing burden of atherosclerotic cardiovascular disease (ASCVD) in the U.S., emphasizing the ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s ...
Cardiovascular disease remains one of the dominant non-communicable causes of death in India, contributing substantially to ...
Despite advancements in treatment and HIV viral suppression, people with HIV experience a risk of myocardial infarction that is 1.73 times higher than in people without HIV.[1][1] Believed to be in ...
Merck & Co. is stepping up to the plate to raise awareness of the dangers of high LDL cholesterol and how it can increase the risk of atherosclerotic cardiovascular disease (ASCVD). Joining the New ...
Swiss pharmaceutical giant Novartis has entered an agreement to acquire Tourmaline Bio for $1.4bn, which will allow the company access to Tourmaline’s lead atherosclerotic cardiovascular disease ...
WEDNESDAY, Sept. 11, 2024 (HealthDay News) -- Breast arterial calcifications (BAC) identified on mammography are associated with the development of both atherosclerotic cardiovascular disease (ASCVD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback